ClinicalTrials.gg
CompletedNCT06982651Updated May 21, 2025

A Study on the Safety, Pharmacokinetics, and Food Effects of MI078 Capsules

A Phase 1 interventional study of MI078 and Placebo in Postpartum Depression, sponsored by Nanjing Minova Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by Nanjing Minova Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Sep 2023, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Depression, Postpartum with a site in China — 9 open to participants now, 10 under way, 1 of them phase 3. Depression, Postpartum · China.

Enrollment
15th of 17
98 · median 270
Started
2023
with 2 others
Phase 1
Only one
of the 20
Registered
13th of 20
by date
Lead sponsor
3 of 20
Nanjing Minova Pharmaceutical Co., Ltd.

Among the 20 studies in Depression, Postpartum with a site in China, this one is the 15th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2023, is the only one in phase 1, and was the 13th registered.

Depression, Postpartum

569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.

Browse Depression, Postpartum studies →

Open to participants now

9 of the 20 studies in Depression, Postpartum with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 87 Depression, Postpartum studies recruiting now, 54 (62%) set no upper age limit and 30 (34%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Depression, Postpartum with a site in China, or all of them as a file.
02

Study summary

This study was divided into three studies, namely, a single administration study, a food impact study, and a multiple administration study.

Read the detailed description

Single-dose study:Eight single-dose cohorts (25 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, and 1000mg) were planned, as described in the table below. In the first and second dose groups (25 mg and 50 mg), a single oral dose of MI078 capsules was given to 1 male and 2 females in a single-center, open-label design. The tolerance and safety of MI078 capsules were evaluated. Dose groups 3-8 were designed in a single-center, randomized, double-blind, placebo-controlled design. Each dose group was planned to enroll 8-10 volunteers, half male and half female (see the table below for details). On the basis of PK and safety data, the actual dose escalation could be adjusted accordingly.

Food Impact Studies:This study adopted a randomized, open, two-sequence, two-cycle crossover design, and the 400 mg dose was selected for the food impact test. Fourteen healthy volunteers, both male and female, were randomly divided into two sequence groups according to the fasting - postprandial and postprandial - fasting administration methods. Each sequence group had 7 volunteers and was divided into two cycles. All volunteers were required to be hospitalized from 1 day before administration to 72 h after administration (day 4). During this hospitalization, volunteers were required to complete the collection of pharmacokinetic samples (blood samples, collection to 72 h after administration). All volunteers could be discharged after the collection of the above biological samples and the corresponding safety assessment. After a washing period of at least 7 days, the second cycle of PK test could be carried out. The collection of PK blood samples and the corresponding safety check in the second cycle were the same as those in the first cycle.

Multiple dosing studies:The multiple-dose study was a single-center, multi-dose, randomized, double-blind, placebo-controlled design. A total of 30 healthy volunteers (half male and half female) were planned to be enrolled. When the higher-dose arm of the single-dose study had been evaluated for tolerability, the multiple-dose study with a sublower dose could proceed. The dose for this study could be adjusted to 250mg for group 3 based on safety and PK data (blinded) from the completed study results (200mg and 400mg groups). MI078 capsules or placebo were administered to 10 volunteers in each of three dose cohorts.

03

Conditions studied

  • Postpartum Depression

Keywords

  • Postpartum Depression
  • MI078
  • Minova
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are willing and able to provide signed to participate in the study and to comply with all study procedures and scheduled visits.
  • Are an adult aged 18 to 45 years, inclusive.
  • Have a between 19.0 and 26.0 kg/m² (inclusive of boundary values) and weigh ≥50.0 kg if male, or ≥45.0 kg if female.
  • Have a total score for suicidal ideation ≤12 points and a score for the dissimulation factor \<4 points on the suicide risk assessment scale at the time of screening.
  • Have regular menstrual cycles, occurring within 28 ± 7 days (female volunteers only).
  • Have had a depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery (if applicable).
  • Are ≤9 months postpartum at Screening (if applicable).

Exclusion criteria

Exclusion Criteria:

  • Have a history or current diagnosis of any diseases of the cardiovascular, endocrine, nervous, digestive, respiratory, urinary, and reproductive systems, hematology, immunology, psychiatry, or metabolic abnormalities, or any other diseases that may interfere with the study results.
  • Have a family history of risk factors for torsades de pointes, or a history of short syndrome, long QT syndrome, unexplained sudden death or drowning in young age (≤40 years), or sudden infant death syndrome in first-degree relatives (i.e., biological parents, siblings, or children).
  • Are engaged in high-altitude work or other occupations involving hazardous mechanical operations.
  • Have a history of allergies to drugs, food, or other substances.
  • Have experienced vomiting within 24 hours before dosing, which is assessed by the investigator to affect the study or impact the safety of the volunteer.
  • Have undergone surgery within 4 weeks before the study or are planned to undergo surgery during the study period.
  • Have taken any medications or health supplements (including traditional Chinese medicine) within 14 days before the study.
  • Have used any drugs that inhibit or induce hepatic drug metabolism within 30 days before the study (e.g., inducers-barbiturates, carbamazepine, phenytoin, , omeprazole; inhibitors-SSRI antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative-hypnotics, verapamil, fluoroquinolones, antihistamines).
  • Have participated in any clinical trial and taken any drug within 3 months before the study.
  • Have donated blood or experienced significant blood loss (≥200 mL, excluding menstrual blood loss in women), received blood transfusions, or used blood products within 3 months before enrollment.
  • Are pregnant or breastfeeding, or cannot use one or more non-pharmacological methods during the study period.
  • Have special dietary requirements that prevent them from adhering to the standardized diet.
  • Consume excessive amounts of tea, coffee, and/or caffeine-containing beverages (more than 8 cups per day, 1 cup = 250 mL).
  • Have consumed excessive amounts of citrus-rich beverages or foods (e.g., grapefruit, oranges) within 48 hours before the first admission to the ward.
  • Are smokers or have smoked more than 5 cigarettes per day within 3 months before the study or cannot refrain from using any tobacco products during the study.
  • Are alcohol abusers or have regularly consumed alcohol within 6 months before the study (i.e., more than 14 units of alcohol per week, 1 unit = 360 mL of beer or 45 mL of 40% spirits or 150 mL of wine) or cannot refrain from using any alcohol-containing products during the study.
  • Are drug abusers or have used soft drugs (e.g., marijuana) within 3 months before the study or hard drugs (e.g., cocaine, phencyclidine) within 1 year before the study.
  • Have abnormal vital signs (systolic blood pressure \<90 mmHg or >140 mmHg, diastolic blood pressure \<50 mmHg or >90 mmHg; pulse rate \<50 bpm or >100 bpm, respiratory rate \<12 breaths per minute or >20 breaths per minute) or abnormal physical examination, (normal ECG requirements: male QTcF ≤450 ms, female QTcF ≤470 ms; PR interval ≤200 ms; QRS complex duration ≤120 ms), or laboratory tests with clinically significant abnormalities (as judged by the clinical research physician).
  • Have positive results for surface antigen, antibody, preliminary screening for antigen/antibody, or syphilis serological reaction.
  • Have difficult venous blood collection or a history of needle fainting or blood fainting, who are deemed unsuitable for enrollment by the investigator.
  • Are likely to be unable to complete the study for other reasons or are deemed ineligible by the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    MI078 capsule

    MI078 capsule

    Drug: MI078

  • Placebo comparator
    placebo

    Placebo of MI078 Capsule

    Drug: Placebo

Interventions

  • DrugMI078

    Dosage Form: Capsule Specification: 25 mg Administration and Dosage: Oral. 1 capsule per dose, once daily. Duration of Treatment: 1 day Dosage Form: Capsule Specification: 50 mg Administration and Dosage: Oral. 1 capsule per dose, once daily. Duration of Treatment: 1 day Dosage Form: Capsule Specification: 200 mg Administration and Dosage: Oral. Options include: * 1 capsule per dose, once daily; * 2 capsules per dose, once daily; * 3 capsules per dose, once daily; * 4 capsules per dose, once daily; Duration of Treatment: 1 day . Dosage Form: Capsule Specification: 200 mg Administration and Dosage: Oral. Options include: * 1 capsule per dose, twice daily; * 2 capsules per dose, twice daily; Duration of Treatment: 7 days . Dosage Form: Capsule Specification: 50mg Administration and Dosage: Oral. Options include: - 5 capsule per dose, Three times a day Duration of Treatment: 3 days .

  • DrugPlacebo

    Placebo of MI078 Capsule

06

What researchers measure

Primary outcomes

  1. Incidence, severity, and causality of AEs, SAEs

    Clinical safety assessments will be conducted for all spontaneously reported and directly observed adverse events (AEs) and serious adverse events (SAEs). AEs should also include abuse-related AEs (such as insomnia, sedation, hallucinations, tremors, and dissociative states) and withdrawal reactions (including headache, anxiety, nausea, vomiting, tremors, decreased attention, irritability, anger, and sleep disturbances).

    Time frame: up to 72 hours after the last dose

  2. vital signs

    Any abnormal changes in vital signs

    Time frame: up to 72 hours after the last dose

  3. SpO₂

    Any abnormal changes in SpO₂ (peripheral capillary oxygen saturation)

    Time frame: up to 72 hours after the last dose

  4. 12-lead electrocardiogram (ECG)

    HR, RR interval, PR interval, QRS complex duration,QTcF=QT/(RR\^0.33)

    Time frame: up to 72 hours after the last dose

  5. Modified Observer's Assessment of Alertness and Sedation Scale(MOAA/S)

    MOAA/S scale is a validated 6-point scale assessing the responsiveness of patients, coinciding with the American Society of Anesthesiologists (ASA) continuum of sedation。The scale rates patient responsiveness as follows: 5:Responds readily to name spoken in normal tone 4:Lethargic response to name spoken in normal tone 3:Responds only after name is called loudly and/or repeatedly 2:Responds only after mild prodding or shaking 1:Responds only after painful trapezius squeeze 0:Does not respond to painful trapezius squeeze

    Time frame: up to 72 hours after the last dose

  6. Stanford Sleepiness Scale (SSS)

    The Stanford Sleepiness Scale (SSS) is a widely used self-assessment tool designed to measure subjective levels of sleepiness or alertness. It consists of a 7-point scale that allows individuals to rate their current level of alertness or sleepiness. The scale is as follows: 1. Feeling active, vital, alert, or wide awake 2. Functioning at a high level, but not at peak; able to concentrate 3. Awake, but relaxed; responsive but not fully alert 4. A little foggy; not at best 5. Foggy; losing interest in remaining awake; slowed down 6. Sleepy, woozy, fighting sleep; prefer to lie down 7. No longer fighting sleep, sleep onset soon; having dream-like thoughts

    Time frame: up to 72 hours after the last dose

Secondary outcomes

  1. Plasma Concentrations of MI078

    PK Parameters of MI078 will be assessed.

    Time frame: up to 72 hours after the last dose

07

Study locations

1 site
  • Third Xiangya Hospital, Central South University
    Changsha, Hunan 410013, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Mar 2024, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 21, 2025
StartActual
Sep 9, 2023
Primary completionActual
Mar 18, 2024
CompletionActual
Mar 18, 2024
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06982651
Lead sponsor
Nanjing Minova Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
May 21, 2025
Start date
Sep 9, 2023
Primary completion
Mar 18, 2024
Completion
Mar 18, 2024
Last update
May 21, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MI078

Start the discussion